Record high FIIs stake in this multibagger pharma stock: Exploring the key tailwinds!
The company saw strong volume growth across key markets, particularly the US, indicating rising demand for their products.
On Tuesday, Indian indices continued their upward trajectory, with the NSE Nifty hitting a new peak of 22,215.60 during trading hours. The bullish trend persisted as both the BSE Sensex and Nifty closed higher for the sixth consecutive session, buoyed by robust buying in banking and financial sectors. The Sensex surged 349.24 points (0.5%) to 73,057.40, while the Nifty climbed 74.70 points (0.3%) to 22,196.95. This positive market sentiment sets the stage for discussing Marksans Pharma's recent quarterly performance, including its Q3 financial figures.
Marksans Pharma Ltd delivered impressive financial results for Q3 FY24. The company witnessed a substantial year-on-year (YOY) sales growth of 22 per cent, reaching Rs 586 crore compared to Rs 480 crore in December 2022. EBIDT soared by an impressive 74 per cent to Rs 133 crore from Rs 76.6 crore in the same period. Net profit also exhibited a notable increase, rising by 33 per cent to Rs 83.0 crore from Rs 62.3 crore. Additionally, EPS showed a healthy uptick of 17 per cent, reaching Rs 1.84 compared to Rs 1.57 in December 2022.
This growth was driven by factors like:
- Market Share Expansion: The company saw strong volume growth across key markets, particularly the US, indicating rising demand for their products.
- Strategic Initiatives: Infrastructure expansion, backward integration plans, and a robust product pipeline are likely contributing to their growth trajectory.
- Favorable Market Conditions: The overall pharmaceutical market landscape may have played a role in their positive performance.
Key Highlights from the Call:
- Robust Growth Across Geographies: Marksans Pharma witnessed notable growth in the UK and EU markets (34 per cent), the US and North America (18 per cent), and other regions.
- Profitability on the Rise: The company's EBITDA margin climbed to 22.7 per cent, driven by operational efficiency, cost optimization, and reduced raw material costs.
- Strategic Roadmap: Marksans outlined key initiatives like infrastructure expansion, backward integration through DMF filings, and increasing production capacity to over 6 billion tablets per annum.
- Focus on OTC and Niche Products: The company plans to capture a significant share of the OTC market and launch 34 new niche, high-value products in the UK over the next two years.
- Positive Outlook: Marksans expects healthy double-digit growth in both the UK and US markets, fueled by their product portfolio, strategic initiatives, and market expansion plans.
Investor Confidence on the Rise:
Institutional investor interest in the stock has risen significantly, with Foreign Institutional Investor (FII) holdings increasing to 15.55 per cent in the quarter ending December 2023 from 4.23 per cent in December 2022. Similarly, Domestic Institutional Investor (DII) holdings surged to 4.76 per cent in December 2023 compared to 0.96 per cent in December 2022. This heightened interest from institutional investors bodes well for the stock's outlook.
Top of Form
Conclusion:
Marksans Pharma's strong Q3 performance, coupled with their strategic roadmap and positive outlook, paints a promising picture for the company's future. Their focus on expanding their production capacity, strengthening their presence in key markets, and launching new niche products positions them well for continued growth. Investors looking for opportunities in the pharmaceutical sector should definitely consider keeping an eye on Marksans Pharma's progress.
The stock is up by 39.75 per cent in the last six months and has delivered multibagger returns of 131.30 per cent in 1 year.
Disclaimer: The article is for informational purposes only and not investment advice
DSIJ’s 'Multibagger Pick’ service recommends well researched multibagger stocks with High Returns potential. If this interests you, do download the service details here.
Related articles
-
Multibagger stock below Rs 200: Keep an eye on this stock, which was locked in the upper circuit on January 20
-
Back-to-back upper circuits: This chocolate manufacturing stock has rallied over 22 per cent in just 5 days, heres why
-
Multi-bagger returns of 600 per cent year to date; don't miss action in this stock that has announced bonus shares!
-
Stock below Rs 200: Keep an eye on this stock, which was locked in the upper circuit on December 22
-
Keep an eye on this stock, which was locked in the upper circuit on December 07
-
Do you own this manufacturing stock that got approval for an Rs 81.60 crore project?
-
Multibagger penny stock under Rs 60 with 200 per cent returns: Heavy buying witnessed in this pharma stock; PAT jumps over 240 per cent!
-
Promoter of defence multibagger stock acquires additional 2,39,800 shares through open offer of this gems and jewelry company
-
Multibagger stock below Rs 20: Aditya Birla Group's stock big fundraising plans; will it be an alpha generator? Promoters to participate!
-
Promoter buying penny stock below Rs 5: Multibagger penny stock with a history of 38 years and 15,000 dealers; watch out!
-
Mukul Agrawal and Tata AIA-backed defence small-cap multibagger stock received a big order from the Ministry of Defence, company aims for Rs 900 crore in revenue!
-
President of India's small-cap stock surpasses Coal India in dividend yield; stock trades at single-digit PE - Check, do you hold?
-
Multibagger solar stock hits back-to-back upper circuits: Bonus and rights issue likely; watch out!
-
Tata group’s multibagger stock RSI above 90: Back-to-back fourth upper circuit; Is it time to book profits or buy on dips?
-
Amansa Holding buys 11,40,301 shares of small-cap multibagger pharma stock; company reduces debt and presents special situation opportunity!
-
On Radar: 90,00,000 warrants issued to promoters; profit doubled in small-cap pharma stock hits 52-week high!
-
President of India's portfolio stock received order of Rs 18,21,33,918 from the Ministry of Defence - Order book Rs 4800 crore!
-
From Rs 1000 to a penny stock below Rs 6: Back-to-back nine upper circuit; Big turnaround after prospective resolution plan?!
-
Highest-ever dividend: Multibagger micro-cap stock with low PE and high dividend yield - A must-watch!
-
FII increased stake in this multibagger pharma stock; Company posted record Q3FY24 profits!